Amedeo Smart

Free Medical Literature Service


 

Amedeo

Migraine

  Free Subscription

Articles published in
Cephalalgia
    March 2024
  1. PASCUAL-MATO M, Garate G, de Prado-Tejerina C, Garcia MJ, et al
    Increased prevalence of migraine in women with inflammatory bowel disease: A cross-sectional study.
    Cephalalgia. 2024;44:3331024241233979.
    >> Share

  2. SELNTIGIA A, Exacoustos C, Ortoleva C, Russo C, et al
    Correlation between endometriosis and migraine features: Results from a prospective case-control study.
    Cephalalgia. 2024;44:3331024241235210.
    >> Share

  3. PORRECA F, Navratilova E, Hirman J, van den Brink AM, et al
    Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
    Cephalalgia. 2024;44:3331024241238153.
    >> Share

  4. THOMSEN AV, Al-Karagholi MA, Hougaard A, Ostrowski SR, et al
    Investigations of the migraine-provoking effect of levcromakalim in patients with migraine with aura.
    Cephalalgia. 2024;44:3331024241237247.
    >> Share

  5. LAMAS PEREZ R, Millan-Vazquez M, Gonzalez-Oria C
    Efficacy and safety of galcanezumab as chronic cluster headache preventive treatment under real world conditions: Observational prospective study.
    Cephalalgia. 2024;44:3331024231226181.
    >> Share

  6. SACCO S, Porreca F
    Breaking barriers in migraine care: Advancing gender medicine to bridge the gap for men.
    Cephalalgia. 2024;44:3331024241238157.
    >> Share

    February 2024
  7. TORRES-FERRUS M, Gallardo VJ, Alpuente A, Caronna E, et al
    Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies.
    Cephalalgia. 2024;44:3331024231222923.
    >> Share

  8. THURAIAIYAH J, Ashina H, Christensen RH, Al-Khazali HM, et al
    Premonitory symptoms in migraine: A REFORM Study.
    Cephalalgia. 2024;44:3331024231223979.
    >> Share

  9. PHILLIPS K, Clerkin-Oliver C, Nirantharakumar K, Crowe FL, et al
    How migraine and its associated treatment impact on pregnancy outcomes: Umbrella review with updated systematic review and meta-analysis.
    Cephalalgia. 2024;44:3331024241229410.
    >> Share

  10. VIANA M, Hougaard A, Tronvik E, Winnberg IG, et al
    Visual migraine aura iconography: A multicentre, cross-sectional study of individuals with migraine with aura.
    Cephalalgia. 2024;44:3331024241234809.
    >> Share

  11. IKUMI N, Marti-Marca A, Torre-Sune A, Cerda-Company X, et al
    Quantifying sensory thresholds along the migraine cycle: An exploratory longitudinal study.
    Cephalalgia. 2024;44:3331024241230279.
    >> Share

  12. TASSORELLI C, Onishchenko K, Halker Singh RB, Duan M, et al
    Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis.
    Cephalalgia. 2024;44:3331024241235156.
    >> Share

  13. SHEWALE AR, Brandenburg JA, Burslem K, Lipton RB, et al
    Health care resource utilization and costs associated with diagnosed medication overuse headache and potential acute medication overuse in individuals with migraine.
    Cephalalgia. 2024;44:3331024241235139.
    >> Share

    January 2024
  14. COPPOLA G, Renzo AD, Parisi V, Serrao M, et al
    Comment on "Lack of reproducibility of resting-state functional MRI findings in migraine with aura".
    Cephalalgia. 2024;44:3331024231225186.
    >> Share

  15. PICO MJ, Badri M, Michalak N, Siefferman JW, et al
    Systemic allergic reaction to galcanezumab (emgality): a case report.
    Cephalalgia. 2024;44:3331024231222914.
    >> Share

  16. NIDDAM DM, Lai KL, Hsiao YT, Wang YF, et al
    Grey matter structure within the visual networks in migraine with aura: multivariate and univariate analyses.
    Cephalalgia. 2024;44:3331024231222637.
    >> Share

  17. BUGGE NS, Grotta Vetvik K, Alstadhaug KB, Braaten T, et al
    Cumulative exposure to estrogen may increase the risk of migraine in women.
    Cephalalgia. 2024;44:3331024231225972.
    >> Share

  18. FLORESCU AM, Lannov LV, Younis S, Cullum CK, et al
    No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study.
    Cephalalgia. 2024;44:3331024231222915.
    >> Share

  19. RAHMAN SM, Luebke AE
    Calcitonin gene-related peptide receptor antagonism reduces motion sickness indicators in mouse migraine models.
    Cephalalgia. 2024;44:3331024231223971.
    >> Share

  20. RAFFAELLI B, Do TP, Chaudhry BA, Amin FM, et al
    Activation of ATP-sensitive potassium channels triggers migraine attacks independent of calcitonin gene-related peptide receptors: a randomized placebo-controlled trial.
    Cephalalgia. 2024;44:3331024231222916.
    >> Share

  21. MONTE G, Papetti L, Ursitti F, Sforza G, et al
    Childhood primary stabbing headache: A double center study.
    Cephalalgia. 2024;44:3331024231225974.
    >> Share

  22. KRISTOFFERSEN ES, Pallesen S, Waage S, Bjorvatn B, et al
    The long-term effect of work schedule, shift work disorder, insomnia and restless legs syndrome on headache among nurses: A prospective longitudinal cohort study.
    Cephalalgia. 2024;44:3331024231226323.
    >> Share

    December 2023
  23. BASEDAU H, Ornello R, Matteis E, Davaasuren B, et al
    Placebo and nocebo in the treatment of migraine: How much does real world effectiveness depend on contextual effects?
    Cephalalgia. 2023;43:3331024231218392.
    >> Share

  24. PENSATO U, Cevoli S, Pierangeli G, Cortelli P, et al
    The evolutionary meaning of migraine.
    Cephalalgia. 2023;43:3331024231209303.
    >> Share

  25. TEZUKA T, Shibata M, Hanaoka H, Izawa Y, et al
    Systemic lupus erythematosus mimicking retinal migraine: a case report.
    Cephalalgia. 2023;43:3331024231219477.
    >> Share

  26. DOBOS D, Kokonyei G, Gyebnar G, Szabo E, et al
    Microstructural differences in migraine: A diffusion-tensor imaging study.
    Cephalalgia. 2023;43:3331024231216456.
    >> Share

  27. AL-KARAGHOLI MA
    Targeting CGRP pathways and aura: A peripheral site with a central effect.
    Cephalalgia. 2023;43:3331024231212895.
    >> Share

  28. CHRISTOPHERSEN P, Dyhring T
    The shortcoming of using glibenclamide in exploratory clinical headache provocation studies.
    Cephalalgia. 2023;43:3331024231219475.
    >> Share

    November 2023
  29. VAN DER AREND B, Terwindt GM
    Response to Letter to the Editor, Comment on "Effect of COVID vaccinations on monthly migraine days".
    Cephalalgia. 2023;43:3331024231208123.
    >> Share

  30. DAUNGSUPAWONG H, Wiwanitkit V
    Comment on "Effect of COVID vaccination on monthly migraine days".
    Cephalalgia. 2023;43:3331024231208121.
    >> Share

  31. AL-KHAZALI HM, Christensen RH, Dodick DW, Chaudhry BA, et al
    Hypersensitivity to opening of ATP-sensitive potassium channels in post-traumatic headache.
    Cephalalgia. 2023;43:3331024231210930.
    >> Share

  32. NAVARRO-PEREZ MP, Santos-Lasaosa S, Olesen J
    Evaluation of the ICHD-3 diagnostic criteria for cardiac cephalalgia and new proposal.
    Cephalalgia. 2023;43:3331024231202243.
    >> Share

  33. HOUGAARD A, Gaist D, Garde E, Iversen P, et al
    Lack of reproducibility of resting-state functional MRI findings in migraine with aura.
    Cephalalgia. 2023;43:3331024231212574.
    >> Share

  34. BAHRA A
    Paroxysmal hemicrania and hemicrania continua: Review on pathophysiology, clinical features and treatment.
    Cephalalgia. 2023;43:3331024231214239.
    >> Share

  35. GARCIA-AZORIN D, Santana-Lopez L, Lozano-Alonso JE, Ordax-Diez A, et al
    InfluenCEF study: Clinical phenotype and duration of headache attributed to influenza infection.
    Cephalalgia. 2023;43:3331024231212900.
    >> Share

  36. ASHINA M, Mitsikostas DD, Amin FM, Kokturk P, et al
    Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study.
    Cephalalgia. 2023;43:3331024231214987.
    >> Share

    October 2023
  37. SEBASTIANELLI G, Casillo F, Abagnale C, Renzo AD, et al
    Central sensitization mechanisms in chronic migraine with medication overuse headache: a study of thalamocortical activation and lateral cortical inhibition.
    Cephalalgia. 2023;43:3331024231202240.
    >> Share

  38. AL-KHAZALI HM, Ashina H, Christensen RH, Wiggers A, et al
    An exploratory analysis of clinical and sociodemographic factors in CGRP-induced migraine attacks: A REFORM study.
    Cephalalgia. 2023;43:3331024231206375.
    >> Share

  39. DEV P, Favas TT, Jaiswal R, Cyriac M, et al
    The effect of low dose thyroid replacement therapy in patients with episodic migraine and subclinical hypothyroidism: A randomised placebo-controlled trial.
    Cephalalgia. 2023;43:3331024231182684.
    >> Share

  40. CHUANG CH, Li JY, King JT, Chen WT, et al
    Abnormal heart rate variability and its application in predicting treatment efficacy in patients with chronic migraine: An exploratory study.
    Cephalalgia. 2023;43:3331024231206781.
    >> Share

  41. CHRISTENSEN RH, Eigenbrodt AK, Ashina H, Steiner TJ, et al
    What proportion of people with migraine report postdromal symptoms? A systematic review and meta-analysis of observational studies.
    Cephalalgia. 2023;43:3331024231206376.
    >> Share

  42. KUAN AS, Chen SP, Wang YF, Wang SJ, et al
    Prolonged headache with vaccine- and dose-specific headache pattern associated with vaccine against SARS-CoV-2 in patients with migraine.
    Cephalalgia. 2023;43:3331024231208110.
    >> Share

  43. ZLOOF Y, Tsur AM, Simchoni M, Derazne E, et al
    Body mass index and migraine in adolescence: A nationwide study.
    Cephalalgia. 2023;43:3331024231209309.
    >> Share

  44. ALEKSOVSKA K, Hershey AD, Deen M, Icco R, et al
    Efficacy and safety of monoclonal antibodies targeting CGRP in migraine prevention. GRADE tables elaborated by the ad hoc working group of the International Headache Society.
    Cephalalgia. 2023;43:3331024231206162.
    >> Share

  45. BELIN AC, Barloese MC
    The genetics and chronobiology of cluster headache.
    Cephalalgia. 2023;43:3331024231208126.
    >> Share

    September 2023
  46. VAN DER AREND BWH, Bloemhof MM, van der Schoor AG, van Zwet EW, et al
    Effect of COVID vaccination on monthly migraine days: a longitudinal cohort study.
    Cephalalgia. 2023;43:3331024231198792.
    >> Share

    August 2023
  47. ALPUENTE A, Torre-Sune A, Caronna E, Gine-Cipres E, et al
    Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: A real-world evidence study.
    Cephalalgia. 2023;43:3331024231177636.
    >> Share

  48. LA ROCCA M, Laporta A, Clemente L, Ammendola E, et al
    Galcanezumab treatment changes visual related EEG connectivity patterns in migraine patients.
    Cephalalgia. 2023;43:3331024231189751.
    >> Share

  49. ADAM I, Elmugabil A, AlHabardi N
    History of maternal migraine and its association with preeclampsia: A case-control study in a low-resource setting in Sudan, Africa.
    Cephalalgia. 2023;43:3000605231193823.
    >> Share

  50. PULEDDA F, Vigano A, Sebastianelli G, Parisi V, et al
    Electrophysiological findings in migraine may reflect abnormal synaptic plasticity mechanisms: A narrative review.
    Cephalalgia. 2023;43:3331024231195780.
    >> Share

  51. LIPTON RB, Halker Singh RB, Mechtler L, McVige J, et al
    Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial.
    Cephalalgia. 2023;51:3331024231190296.
    >> Share

    July 2023
  52. PATTERSON GENTILE C, Aguirre GK, Hershey AD, Szperka CL, et al
    Symptoms associated with headache in youth.
    Cephalalgia. 2023;43:3331024231187162.
    >> Share

    June 2023
  53. VERHAGEN IE, van der Arend BW, van Casteren DS, Thiermann NJ, et al
    Migraine with and without aura in relation to the menstrual cycle and other hormonal milestones: A prospective cohort study.
    Cephalalgia. 2023;43:3331024231164322.
    >> Share

  54. PELZER N, de Boer I, van den Maagdenberg AMJM, Terwindt GM, et al
    Neurological and psychiatric comorbidities of migraine: Concepts and future perspectives.
    Cephalalgia. 2023;43:3331024231180564.
    >> Share

  55. KLAN T, Gaul C, Liesering-Latta E, Witthoft M, et al
    Behavioral treatment for migraine prophylaxis in adults: Moderator analysis of a randomized controlled trial.
    Cephalalgia. 2023;43:3331024231178237.
    >> Share

  56. BERTZ R, Bhardwaj R, Morris BA, Ashbrenner E, et al
    A placebo-controlled, randomized, single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of rimegepant in healthy participants.
    Cephalalgia. 2023;43:3331024231179131.
    >> Share

  57. BUTURE A, Tomkins EM, Shukralla A, Troy E, et al
    Two-year, real-world erenumab persistence and quality of life data in 82 pooled patients with abrupt onset, unremitting, treatment refractory headache and a migraine phenotype: New daily persistent headache or persistent post-traumatic headache in the
    Cephalalgia. 2023;43:3331024231182126.
    >> Share

  58. ADAMS AM, Buse DC, Leroux E, Lanteri-Minet M, et al
    Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) Study: Methods and multi-country baseline findings for diagnosis rates and care.
    Cephalalgia. 2023;43:3331024231180611.
    >> Share

  59. CARCEL C, Haghdoost F, Shen J, Nanda P, et al
    The effect of blood pressure lowering medications on the prevention of episodic migraine: A systematic review and meta-analysis.
    Cephalalgia. 2023;43:3331024231183166.
    >> Share

  60. THOMSEN AV, Puonti O, Gaist D, Kyvik KO, et al
    Investigations of the subarachnoid space as a potential link between aura and headache in migraine: A case-control MRI study.
    Cephalalgia. 2023;43:3331024231170541.
    >> Share

  61. CONSTANTINIDIS TS, Arvaniti C, Fakas N, Rudolf J, et al
    The prevalence and burden of medication overuse headache in Greece.
    Cephalalgia. 2023;43:3331024231184909.
    >> Share

    May 2023
  62. VAN DER AREND BWH, Verhagen IE, van Leeuwen M, van der Arend MQTP, et al
    Defining migraine days, based on longitudinal E-diary data.
    Cephalalgia. 2023;43:3331024231166625.
    >> Share

  63. CHEEMA S, Mehta D, Ray JC, Hutton EJ, et al
    New daily persistent headache: A systematic review and meta-analysis.
    Cephalalgia. 2023;43:3331024231168089.
    >> Share

  64. STUBBERUD A, Ingvaldsen SH, Brenner E, Winnberg I, et al
    Forecasting migraine with machine learning based on mobile phone diary and wearable data.
    Cephalalgia. 2023;43:3331024231169244.
    >> Share

  65. ASHINA M, Lanteri-Minet M, Ettrup A, Christoffersen CL, et al
    Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study.
    Cephalalgia. 2023;43:3331024231170807.
    >> Share

  66. VAN WELIE RF, van Welie FC, de Vries Lentsch S, Dahan A, et al
    Characterizing opioid use in a Dutch cohort with migraine.
    Cephalalgia. 2023;43:3331024231174160.
    >> Share

  67. HSIAO FJ, Chen WT, Wang YF, Chen SP, et al
    Identification of patients with chronic migraine by using sensory-evoked oscillations from the electroencephalogram classifier.
    Cephalalgia. 2023;43:3331024231176074.
    >> Share

  68. GULDIKEN YC, Petropoulos IN, Malik A, Malik RA, et al
    Corneal confocal microscopy identifies corneal nerve fiber loss in patients with migraine.
    Cephalalgia. 2023;43:3331024231170810.
    >> Share

  69. RUSCHEWEYH R, Dresler T, Forderreuther S, Gaul C, et al
    What do patients' efficacy and tolerability ratings of acute migraine medication tell us? Cross-sectional data from the DMKG Headache Registry.
    Cephalalgia. 2023;43:3331024231174855.
    >> Share

  70. STEINER TJ
    Classification of migraine and tension-type headache: A response to the proposals of Olesen.
    Cephalalgia. 2023;43:3331024231169240.
    >> Share

  71. SUZUKI K, Suzuki S, Shiina T, Tatsumoto M, et al
    Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan.
    Cephalalgia. 2023;43:3331024231177649.
    >> Share

  72. PARK CG, Na HY, Park DE, Kim HY, et al
    Altered interictal serum histamine and immunoglobulin E but unchanged tryptase levels in individuals with episodic and chronic migraine.
    Cephalalgia. 2023;43:3331024231178218.
    >> Share

  73. ABU-ARAFEH I, Hershey AD, Diener HC, Tassorelli C, et al
    Guidelines Update: Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition - An experience-based update.
    Cephalalgia. 2023;43:3331024231178239.
    >> Share

    April 2023
  74. GIRI S, Tronvik E, Linde M, Pedersen SA, et al
    Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis.
    Cephalalgia. 2023;43:3331024231156922.
    >> Share

  75. OLESEN J, Jensen RH
    The Global Campaign Against Headache and its future relation to IHS and WHO.
    Cephalalgia. 2023;43:3331024231159625.
    >> Share

  76. HAGHDOOST F, Puledda F, Garcia-Azorin D, Huessler EM, et al
    Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.
    Cephalalgia. 2023;43:3331024231159366.
    >> Share

  77. NIDDAM DM, Wu SW, Lai KL, Yang YY, et al
    An altered reward system characterizes chronic migraine with medication overuse headache.
    Cephalalgia. 2023;43:3331024231158088.
    >> Share

  78. ASAWAVICHIENJINDA T, Sathitratanacheewin S, Chokesuwattanaskul R
    "Wearing-off" efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials.
    Cephalalgia. 2023;43:3331024231161261.
    >> Share

  79. IANNONE LF, Burgalassi A, Vigani G, Tabasso G, et al
    Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study.
    Cephalalgia. 2023;43:3331024231160519.
    >> Share

  80. FAVONI V, Mascarella D, Giannini G, Bauleo S, et al
    Prevalence, natural history and dynamic nature of chronic headache and medication overuse headache in Italy: The SPARTACUS study.
    Cephalalgia. 2023;43:3331024231157677.
    >> Share

  81. ASHINA M, Roos C, Li LQ, Komori M, et al
    Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION randomized trial.
    Cephalalgia. 2023;43:3331024231161745.
    >> Share

  82. ZHANG L, Zhou Y, Wang Y, Yang L, et al
    Inhibiting PAC1 receptor internalization and endosomal ERK pathway activation may ameliorate hyperalgesia in a chronic migraine rat model.
    Cephalalgia. 2023;43:3331024231163131.
    >> Share

  83. RUSSO CV, Sacca F, Braca S, Sansone M, et al
    Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: A prospective observational cohort study.
    Cephalalgia. 2023;43:3331024231161809.
    >> Share

  84. OLESEN J
    Classification of migraine and tension-type headache.
    Cephalalgia. 2023;43:3331024221139238.
    >> Share

  85. CROWE HM, Wesselink AK, Hatch EE, Wise LA, et al
    Migraine and risk of hypertensive disorders of pregnancy: A population-based cohort study.
    Cephalalgia. 2023;43:3331024231161746.
    >> Share

  86. SAKAI F, Igarashi H, Yokoyama M, Begasse de Dhaem O, et al
    Diagnosis, knowledge, perception, and productivity impact of headache education and clinical evaluation program in the workplace at an information technology company of more than 70,000 employees.
    Cephalalgia. 2023;43:3331024231165682.
    >> Share

    March 2023
  87. MESSINA R, Huessler EM, Puledda F, Haghdoost F, et al
    Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.
    Cephalalgia. 2023;43:3331024231152169.
    >> Share

  88. MYKLAND MS, Uglem M, Bjork MH, Matre D, et al
    Effects of insufficient sleep on sensorimotor processing in migraine: A randomised, blinded crossover study of event related beta oscillations.
    Cephalalgia. 2023;43:3331024221148398.
    >> Share

  89. PULEDDA F, Tassorelli C, Diener HC
    New migraine drugs.
    Cephalalgia. 2023;43:3331024221144784.
    >> Share

  90. LEE MJ, Peng KP
    Other primary headaches: Distinct clinical features and uncertain pathophysiology.
    Cephalalgia. 2023;43:3331024221147870.
    >> Share

  91. PULEDDA F, Younis S, Huessler EM, Haghdoost F, et al
    Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature.
    Cephalalgia. 2023;43:3331024231151419.
    >> Share

  92. CARLSEN LN, Hansen CS, Kogelman LJA, Werge TM, et al
    DNA-methylation and immunological response in medication overuse headache.
    Cephalalgia. 2023;43:3331024221147482.
    >> Share

  93. EVERS S
    Cephalalgia - The early history.
    Cephalalgia. 2023;43:3331024221148128.
    >> Share

  94. MYKLAND MS, Uglem M, Stovner LJ, Brenner E, et al
    Insufficient sleep may alter cortical excitability near the migraine attack: A blinded TMS crossover study.
    Cephalalgia. 2023;43:3331024221148391.
    >> Share

  95. ASHINA S, Melo-Carrillo A, Szabo E, Borsook D, et al
    Pre-treatment non-ictal cephalic allodynia identifies responders to prophylactic treatment of chronic and episodic migraine patients with galcanezumab: A prospective quantitative sensory testing study (NCT04271202).
    Cephalalgia. 2023;43:3331024221147881.
    >> Share

    February 2023
  96. RAFFAELLI B, De Icco R, Corrado M, Terhart M, et al
    Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review.
    Cephalalgia. 2023;43:3331024221137091.
    >> Share

  97. AL-KARAGHOLI MA, Kalatharan V, Ghanizada H, Gram C, et al
    Prolactin in headache and migraine: A systematic review of clinical studies.
    Cephalalgia. 2023;43:3331024221136286.
    >> Share

  98. LEE MJ, Al-Karagholi MA, Reuter U
    New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy.
    Cephalalgia. 2023;43:3331024221146315.
    >> Share

  99. HARDER AV, Terwindt GM, Nyholt DR, van den Maagdenberg AM, et al
    Migraine genetics: Status and road forward.
    Cephalalgia. 2023;43:3331024221145962.
    >> Share

  100. GALLARDO VJ, Vila-Pueyo M, Pozo-Rosich P
    The impact of epigenetic mechanisms in migraine: Current knowledge and future directions.
    Cephalalgia. 2023;43:3331024221145916.
    >> Share

  101. NIKOLOVA S, Chong CD, Dumkrieger GM, Li J, et al
    Longitudinal differences in iron deposition in periaqueductal gray matter and anterior cingulate cortex are associated with response to erenumab in migraine.
    Cephalalgia. 2023;43:3331024221144783.
    >> Share

  102. KWON S, Lee MJ, Kim M
    Epicranial headache part 1: Primary stabbing headache.
    Cephalalgia. 2023;43:3331024221146985.
    >> Share

  103. SCHRAMM S, Borner C, Reichert M, Baum T, et al
    Functional magnetic resonance imaging in migraine: A systematic review.
    Cephalalgia. 2023;43:3331024221128278.
    >> Share

  104. DE BOER I, Verhagen IE, Souza MNP, Ashina M, et al
    Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies.
    Cephalalgia. 2023;43:3331024221143773.
    >> Share

  105. RUIZ M, Cocores A, Tosti A, Goadsby PJ, et al
    Alopecia as an emerging adverse event to CGRP monoclonal antibodies: Cases Series, evaluation of FAERS, and literature review.
    Cephalalgia. 2023;43:3331024221143538.
    >> Share

  106. CHOWDHURY D, Tomar A, Deorari V, Duggal A, et al
    Greater occipital nerve blockade for the preventive treatment of chronic migraine: A randomized double-blind placebo-controlled study.
    Cephalalgia. 2023;43:3331024221143541.
    >> Share

  107. LIPTON RB, Blumenfeld A, Jensen CM, Croop R, et al
    Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials.
    Cephalalgia. 2023;43:3331024221141686.
    >> Share

  108. MEISE R, Carvalho GF, Thiel C, Luedtke K, et al
    Additional effects of pain neuroscience education combined with physiotherapy on the headache frequency of adult patients with migraine: A randomized controlled trial.
    Cephalalgia. 2023;43:3331024221144781.
    >> Share

  109. TASNIM S, Wilson SG, Walsh JP, Nyholt DR, et al
    Shared genetics and causal relationships between migraine and thyroid function traits.
    Cephalalgia. 2023;43:3331024221139253.
    >> Share

  110. BEGASSE DE DHAEM O, Takizawa T, Dodick DW
    Long-term open-label and real-world studies of lasmiditan, ubrogepant, and rimegepant for the acute treatment of migraine attacks.
    Cephalalgia. 2023;43:3331024221137092.
    >> Share

  111. VILA-PUEYO M, Cuenca-Leon E, Queiros AC, Kulis M, et al
    Genome-wide DNA methylation analysis in an antimigraine-treated preclinical model of cortical spreading depolarization.
    Cephalalgia. 2023;43:3331024221146317.
    >> Share

    January 2023
  112. PATTERSON GENTILE C, Aguirre GK, Hershey AD, Szperka CL, et al
    Comparison of continuous headache features in youth with migraine, new daily persistent headache, and persistent post-traumatic headache.
    Cephalalgia. 2023;43:3331024221131331.
    >> Share

  113. SCUTELNIC A, Petroulia V, Schraml L, Jung S, et al
    The "index vein" as a sign for migraine aura in the emergency setting.
    Cephalalgia. 2023;43:3331024221132010.
    >> Share

  114. ACARSOY C, Fani L, Al-Hassany L, Berghout B, et al
    Migraine and the risk of stroke in a middle-aged and elderly population: A prospective cohort study.
    Cephalalgia. 2023;43:3331024221132008.
    >> Share

  115. KURTH T, Rohmann JL
    Studying migraine as a risk factor for stroke: The importance of working with an explicit causal framework.
    Cephalalgia. 2023;43:3331024221132007.
    >> Share

  116. KLEIN BC, Miceli R, Severt L, McAllister P, et al
    Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial.
    Cephalalgia. 2023;43:3331024221128250.
    >> Share

  117. PACHECO-BARRIOS K, Velasquez-Rimachi V, Navarro-Flores A, Huerta-Rosario A, et al
    Primary headache disorders in Latin America and the Caribbean: A meta-analysis of population-based studies.
    Cephalalgia. 2023;43:3331024221128265.
    >> Share

  118. CARONNA E, van den Hoek TC, Bolay H, Garcia-Azorin D, et al
    Headache attributed to SARS-CoV-2 infection, vaccination and the impact on primary headache disorders of the COVID-19 pandemic: A comprehensive review.
    Cephalalgia. 2023;43:3331024221131337.
    >> Share

  119. FURIA A, Liguori R, Donadio V
    Recurrent Painful Ophthalmoplegic Neuropathy: A case report with atypical features and a review of the literature.
    Cephalalgia. 2023;43:3331024221133386.
    >> Share

  120. CHWOLKA M, Goadsby PJ, Gantenbein AR
    Comorbidity or combination - more evidence for cluster-migraine?
    Cephalalgia. 2023;43:3331024221133383.
    >> Share

    November 2022
  121. SAMPATAKAKIS SN, Lymperopoulos L, Mavridis T, Karagiorgis G, et al
    Visual snow: A systematic review and a case series.
    Cephalalgia. 2022;42:1409-1419.
    >> Share

  122. CITAK A, Kilinc E, Torun IE, Ankarali S, et al
    The effects of certain TRP channels and voltage-gated KCNQ/Kv7 channel opener retigabine on calcitonin gene-related peptide release in the trigeminovascular system.
    Cephalalgia. 2022;42:1375-1386.
    >> Share

  123. BASEDAU H, Oppermann T, Gundelwein Silva E, Peng KP, et al
    Galcanezumab modulates Capsaicin-induced C-fiber reactivity.
    Cephalalgia. 2022;42:1331-1338.
    >> Share

    October 2022
  124. MARTINS-OLIVEIRA M, Akerman S, Holland PR, Tavares I, et al
    Pharmacological modulation of ventral tegmental area neurons elicits changes in trigeminovascular sensory processing and is accompanied by glycemic changes: Implications for migraine.
    Cephalalgia. 2022 Oct 18:3331024221110111. doi: 10.1177/03331024221110111.
    >> Share

  125. RIESENBERG R, Gaul C, Stroud CE, Dong Y, et al
    Long-term open-label safety study of galcanezumab in patients with episodic or chronic cluster headache.
    Cephalalgia. 2022;42.
    >> Share

  126. EVERS S, Holle-Lee D, Schankin CJ, Kull P, et al
    Visual snow syndrome is probably not mediated by CGRP: A case series.
    Cephalalgia. 2022;42.
    >> Share

  127. LANGER LK, Bayley MT, Lawrence DW, Comper P, et al
    Revisiting the ICHD-3 criteria for headache attributed to mild traumatic injury to the head: Insights from the Toronto Concussion Study Analysis of Acute Headaches Following Concussion.
    Cephalalgia. 2022;42.
    >> Share

  128. RAY JC, Pham X, Foster E, Cheema S, et al
    The prevalence of headache disorders in Postural Tachycardia Syndrome: A systematic review and meta-analysis of the literature.
    Cephalalgia. 2022;42.
    >> Share

    September 2022
  129. LANTERI-MINET M, Ducros A, Francois C, Olewinska E, et al
    Effectiveness of onabotulinumtoxinA (BOTOX(R)) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data.
    Cephalalgia. 2022 Sep 8:3331024221123058. doi: 10.1177/03331024221123058.
    >> Share

  130. TSAO YC, Wang YF, Fuh JL, Chen WT, et al
    Non-aura visual disturbance with high visual aura rating scale scores has stronger association with migraine chronification than typical aura.
    Cephalalgia. 2022 Sep 6:3331024221123074. doi: 10.1177/03331024221123074.
    >> Share

  131. KELLIER DJ, Marquez de Prado B, Haagen D, Grabner P, et al
    Development of a text message-based headache diary in adolescents and children.
    Cephalalgia. 2022;42:1013-1021.
    >> Share

    August 2022
  132. MACGREGOR EA, Komori M, Krege JH, Baygani S, et al
    Efficacy of lasmiditan for the acute treatment of perimenstrual migraine.
    Cephalalgia. 2022 Aug 18:3331024221118929. doi: 10.1177/03331024221118929.
    >> Share

  133. THURAIAIYAH J, Erritzoe-Jervild M, Al-Khazali HM, Schytz HW, et al
    The role of cytokines in migraine: A systematic review.
    Cephalalgia. 2022 Aug 12:3331024221118924. doi: 10.1177/03331024221118924.
    >> Share

  134. HENDRIKSE ER, Rees TA, Tasma Z, Le Foll C, et al
    Calcitonin receptor antibody validation and expression in the rodent brain.
    Cephalalgia. 2022;42:815-826.
    >> Share

  135. STRASSMAN AM, Melo-Carrillo A, Houle TT, Adams A, et al
    Atogepant - an orally-administered CGRP antagonist - attenuates activation of meningeal nociceptors by CSD.
    Cephalalgia. 2022;42:933-943.
    >> Share

  136. THUNSTEDT DC, Schmutzer M, Fabritius MP, Thorsteinsdottir J, et al
    Headache characteristics and postoperative course in Chiari I malformation.
    Cephalalgia. 2022;42:879-887.
    >> Share

    July 2022
  137. IKUMI N, Cerda-Company X, Marti-Marca A, Vila-Ballo A, et al
    Avoidance behaviour modulates but does not condition phonophobia in migraine.
    Cephalalgia. 2022 Jul 9:3331024221111772. doi: 10.1177/03331024221111772.
    >> Share

  138. OLESEN J
    Personal view: Modelling pain mechanisms of migraine without aura.
    Cephalalgia. 2022 Jul 7:3331024221111529. doi: 10.1177/03331024221111529.
    >> Share

  139. STEINER TJ, Terwindt GM, Katsarava Z, Pozo-Rosich P, et al
    Migraine-attributed burden, impact and disability, and migraine-impacted quality of life: Expert consensus on definitions from a Delphi process.
    Cephalalgia. 2022 Jul 5:3331024221110102. doi: 10.1177/03331024221110102.
    >> Share

  140. VIGANO A, Toscano M, Petolicchio B, Bianchi A, et al
    Letter to the editor regarding "Efficacy and tolerability of combination treatment of topiramate and greater occipital nerve block versus topiramate monotherapy for the preventive treatment of chronic migraine: A randomized controlled trial".
    Cephalalgia. 2022 Jul 3:3331024221111528. doi: 10.1177/03331024221111528.
    >> Share

  141. BRANDT RB, Cnossen VM, Doesborg PG, Coo IF, et al
    Unilateral increased visual sensitivity in cluster headache: a cross-sectional study.
    Cephalalgia. 2022;42:722-729.
    >> Share

  142. ZHOU Y, Zhang F, Starcevic Manning M, Hu Z, et al
    Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions.
    Cephalalgia. 2022;42:749-760.
    >> Share

  143. IANNONE LF, De Cesaris F, Ferrari A, Benemei S, et al
    Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine.
    Cephalalgia. 2022 Jul 1:3331024221111526. doi: 10.1177/03331024221111526.
    >> Share

    June 2022
  144. MAKAREVICIUS G, Ryliskiene K
    Successful treatment of primary headache associated with sexual activity using erenumab: Case report.
    Cephalalgia. 2022;42:680-683.
    >> Share

  145. OLIVEIRA R, Placido M, Pereira L, Machado S, et al
    Headaches and the use of personal protective equipment in the general population during the COVID-19 pandemic.
    Cephalalgia. 2022;42:608-617.
    >> Share

  146. PENSATO U, Baraldi C, Favoni V, Mascarella D, et al
    Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache.
    Cephalalgia. 2022;42:645-653.
    >> Share

  147. RAIBIN K, Markus TE
    Cutaneous allodynia in pediatric and adolescent patients and their mothers: A comparative study.
    Cephalalgia. 2022;42:579-589.
    >> Share

    May 2022
  148. SUDAT SE, Jacobson AS, Avins AL, Lipton RB, et al
    A population-health approach to characterizing migraine by comorbidity: Results from the Mindfulness and Migraine Cohort Study.
    Cephalalgia. 2022 May 31:3331024221104180. doi: 10.1177/03331024221104180.
    >> Share

  149. CHRISTENSEN CG, Techlo TR, Kogelman LJ, Wegner Thorner L, et al
    Population-based prevalence of cranial autonomic symptoms in migraine and proposed diagnostic appendix criteria.
    Cephalalgia. 2022 May 29:3331024221094548. doi: 10.1177/03331024221094548.
    >> Share

  150. EVERS S, Frese A, Summ O, Husstedt IW, et al
    Levetiracetam in the prophylactic treatment of episodic migraine: A prospective open label study.
    Cephalalgia. 2022 May 27:3331024221103815. doi: 10.1177/03331024221103815.
    >> Share

  151. MOUAANAKI SA, Carlsen LN, Bendtsen L, Jensen RH, et al
    Treatment experiences and clinical characteristics in migraine and tension-type headache patients before the first visit to a tertiary headache center.
    Cephalalgia. 2022 May 27:3331024221104178. doi: 10.1177/03331024221104178.
    >> Share

  152. VERHAGEN IE, Spaink HA, van der Arend BW, van Casteren DS, et al
    Validation of diagnostic ICHD-3 criteria for menstrual migraine.
    Cephalalgia. 2022 May 6:3331024221099031. doi: 10.1177/03331024221099031.
    >> Share

  153. HELFENSTEIN C, Strupf M, Stefke A, Fraunberger B, et al
    Cyclic changes of sensory parameters in migraine patients.
    Cephalalgia. 2022 May 6:3331024221097932. doi: 10.1177/03331024221097932.
    >> Share

  154. NOSER AE, Klages KL, Gamwell KL, Brammer CN, et al
    A systematic evaluation of primary headache management apps leveraging behavior change techniques.
    Cephalalgia. 2022;42:510-523.
    >> Share

  155. CHIANG CC, Shahid AH, Harriott AM, Tietjen GE, et al
    Evaluation and treatment of headache associated with moyamoya disease - a narrative review.
    Cephalalgia. 2022;42:542-552.
    >> Share

    April 2022
  156. GEPPETTI P, De Cesaris F, Benemei S, Cortelli P, et al
    Self-administered subcutaneous diclofenac sodium in acute migraine attack: A randomized, double-blind, placebo-controlled dose-finding pilot study.
    Cephalalgia. 2022 Apr 26:3331024221093712. doi: 10.1177/03331024221093712.
    >> Share

  157. MOHAMAD SAFIAI NI, Mohamad NA, Basri H, Inche Mat LN, et al
    High-frequency repetitive transcranial magnetic stimulation at dorsolateral prefrontal cortex for migraine prevention: A systematic review and meta-analysis.
    Cephalalgia. 2022 Apr 17:3331024221092423. doi: 10.1177/03331024221092423.
    >> Share

  158. PAN LH, Wang YF, Ling YH, Lai KL, et al
    Pain sensitivities predict prophylactic treatment outcomes of flunarizine in chronic migraine patients: A prospective study.
    Cephalalgia. 2022 Apr 11:3331024221080572. doi: 10.1177/03331024221080572.
    >> Share

  159. NIKOLOVA S, Schwedt TJ, Li J, Wu T, et al
    T2* reduction in patients with acute post-traumatic headache.
    Cephalalgia. 2022;42.
    >> Share

    March 2022
  160. DI ANTONIO S, Arendt-Nielsen L, Ponzano M, Bovis F, et al
    Cervical musculoskeletal impairments in the 4 phases of the migraine cycle in episodic migraine patients.
    Cephalalgia. 2022 Mar 25:3331024221082506. doi: 10.1177/03331024221082506.
    >> Share

  161. PETRUSIC I, Jovanovic V, Kovic V, Savic AM, et al
    P3 latency as a biomarker for the complexity of migraine with aura: Event-related potential study.
    Cephalalgia. 2022 Mar 25:3331024221090204. doi: 10.1177/03331024221090204.
    >> Share

  162. BUTT JH, S Eddelien H, Kruuse C
    The headache and aura-inducing effects of sildenafil in patients with migraine with aura.
    Cephalalgia. 2022 Mar 25:3331024221088998. doi: 10.1177/03331024221088998.
    >> Share

  163. MCALLISTER P, Kudrow D, Cady R, Hirman J, et al
    Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine.
    Cephalalgia. 2022 Mar 25:3331024221089567. doi: 10.1177/03331024221089567.
    >> Share

  164. FERNANDEZ-DE-LAS-PENAS C, Navarro-Santana MJ, Curiel-Montero F, Plaza-Manzano G, et al
    Localized and widespread pressure pain hypersensitivity in patients with episodic or chronic migraine: A systematic review and meta-analysis.
    Cephalalgia. 2022 Mar 25:3331024221084217. doi: 10.1177/03331024221084217.
    >> Share

  165. DIENER HC, McAllister P, Jurgens TP, Kessler Y, et al
    Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.
    Cephalalgia. 2022 Mar 25:3331024221076485. doi: 10.1177/03331024221076485.
    >> Share

  166. ASHINA M, McAllister P, Cady R, Hirman J, et al
    Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2.
    Cephalalgia. 2022 Mar 18:3331024221077646. doi: 10.1177/03331024221077646.
    >> Share

  167. WANG YF, Liao YC, Tzeng YS, Chen SP, et al
    Mutation screening and association analysis of NOTCH3 p.R544C in patients with migraine with or without aura.
    Cephalalgia. 2022 Mar 18:3331024221080891. doi: 10.1177/03331024221080891.
    >> Share

  168. KWON S, Gil YE, Lee MJ
    Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients.
    Cephalalgia. 2022 Mar 18:3331024221076481. doi: 10.1177/03331024221076481.
    >> Share

  169. MILOSEVIC N, Trajkovic JZ, Mijajlovic M, Milosevic J, et al
    The burden and health care use of patients with migraine and tension-type headache in post-conflict area of Serbia.
    Cephalalgia. 2022 Mar 18:3331024221082061. doi: 10.1177/03331024221082061.
    >> Share

  170. HIRTZ C, Adam G, Raposo N, Fabre N, et al
    Diagnostic utility of T2*-weighted GRE in migraine with aura attack. The cortical veins sign.
    Cephalalgia. 2022 Mar 18:3331024221076484. doi: 10.1177/03331024221076484.
    >> Share

  171. THURAIAIYAH J, Kokoti L, Al-Karagholi MA, Ashina M, et al
    Involvement of adenosine signaling pathway in migraine pathophysiology: A systematic review of clinical studies.
    Cephalalgia. 2022 Mar 18:3331024221077665. doi: 10.1177/03331024221077665.
    >> Share

  172. CHOWDHURY D, Mundra A, Datta D, Duggal A, et al
    Efficacy and tolerability of combination treatment of topiramate and greater occipital nerve block versus topiramate monotherapy for the preventive treatment of chronic migraine: A randomized controlled trial.
    Cephalalgia. 2022 Mar 8:3331024221082077. doi: 10.1177/03331024221082077.
    >> Share

  173. VAZ JM, Alves BM, Duarte DB, Marques LA, et al
    Quality appraisal of existing guidelines for the management of headache disorders by the AGREE II's method.
    Cephalalgia. 2022;42:239-249.
    >> Share

    February 2022
  174. MATAMALA-GOMEZ M, Bottiroli S, Sances G, Allena M, et al
    Facial expressions modulate pain perception in patients with chronic migraine.
    Cephalalgia. 2022 Feb 15:3331024221075081. doi: 10.1177/03331024221075081.
    >> Share

  175. SEBASTIANELLI G, Abagnale C, Casillo F, Cioffi E, et al
    Bimodal sensory integration in migraine: A study of the effect of visual stimulation on somatosensory evoked cortical responses.
    Cephalalgia. 2022 Feb 15:3331024221075073. doi: 10.1177/03331024221075073.
    >> Share

  176. KIM J, Park CG, Chu MK
    Interictal plasma endothelin-1 levels do not change in individuals with episodic and chronic migraine.
    Cephalalgia. 2022 Feb 15:3331024221075616. doi: 10.1177/03331024221075616.
    >> Share

  177. STOVNER LJ, Hagen K, Tronvik E, Bruvik Gravdahl G, et al
    FollowTheSutures: Piloting a new way to administer onabotulinumtoxinA for chronic migraine.
    Cephalalgia. 2022 Feb 15:3331024211067775. doi: 10.1177/03331024211067775.
    >> Share

  178. NUOTTAMO ME, Happola P, Artto V, Hautakangas H, et al
    NCOR2 is a novel candidate gene for migraine-epilepsy phenotype.
    Cephalalgia. 2022 Feb 15:3331024211068065. doi: 10.1177/03331024211068065.
    >> Share

  179. AL-KHAZALI HM, Younis S, Al-Sayegh Z, Ashina S, et al
    Prevalence of neck pain in migraine: A systematic review and meta-analysis.
    Cephalalgia. 2022 Feb 15:3331024211068073. doi: 10.1177/03331024211068073.
    >> Share

  180. MESSLINGER K, Neuhuber W, May A
    Activation of the trigeminal system as a likely target of SARS-CoV-2 may contribute to anosmia in COVID-19.
    Cephalalgia. 2022;42:176-180.
    >> Share

    January 2022
  181. NAJIB U, Smith T, Hindiyeh N, Saper J, et al
    Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial.
    Cephalalgia. 2022 Jan 9:3331024211068813. doi: 10.1177/03331024211068813.
    >> Share

  182. MCGINLEY JS, Houts CR, Wirth RJ, Lipton RB, et al
    Measuring headache day severity using multiple features in daily diary designs.
    Cephalalgia. 2022;42:53-62.
    >> Share

    December 2021
  183. ELIZAGARAY-GARCIA I, Carvalho GF, Szikszay TM, Adamczyk WM, et al
    Psychophysical testing in chronic migraine and chronic tension type headache: An observational study.
    Cephalalgia. 2021 Dec 7:3331024211060315. doi: 10.1177/03331024211060315.
    >> Share

  184. OLIVEIRA AB, Mercante JPP, Peres MFP, Molina MDCB, et al
    Physical inactivity and headache disorders: Cross-sectional analysis in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).
    Cephalalgia. 2021;41:1467-1485.
    >> Share

  185. NERI I, Menichini D, Monari F, Bascio LS, et al
    Perinatal outcomes in women affected by different types of headache disorders: A prospective cohort study.
    Cephalalgia. 2021;41:1492-1498.
    >> Share

    November 2021
  186. CHRISTENSEN SL, Rasmussen RH, Cour S, Ernstsen C, et al
    Smooth muscle ATP-sensitive potassium channels mediate migraine-relevant hypersensitivity in mouse models.
    Cephalalgia. 2021 Nov 24:3331024211053570. doi: 10.1177/03331024211053570.
    >> Share

  187. MALEKIAN N, Bastani PB, Oveisgharan S, Nabaei G, et al
    Preventive effect of greater occipital nerve block on patients with episodic migraine: A randomized double-blind placebo-controlled clinical trial.
    Cephalalgia. 2021 Nov 17:3331024211058182. doi: 10.1177/03331024211058182.
    >> Share

  188. CHHABRA N, Chiang CC, Di Nome MA, Houghton O, et al
    Migrainous infarction of the eye: Two cases of monocular ischemic complications associated with retinal migraine.
    Cephalalgia. 2021 Nov 17:3331024211056286. doi: 10.1177/03331024211056286.
    >> Share

  189. NEVERDAHL JP, Uglem M, Matre D, Hansen JO, et al
    Pain thresholds and suprathreshold pain after sleep restriction in migraine - A blinded crossover study.
    Cephalalgia. 2021 Nov 17:3331024211056565. doi: 10.1177/03331024211056565.
    >> Share

  190. TOGHA M, Martami F, Jafari E, Ariyanfar S, et al
    The prevalence and characteristics of visceral autonomic symptoms among migraineurs: A population-based study.
    Cephalalgia. 2021 Nov 17:3331024211056849. doi: 10.1177/03331024211056849.
    >> Share

  191. REUTER U, Ehrlich M, Gendolla A, Heinze A, et al
    Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial.
    Cephalalgia. 2021 Nov 7:3331024211053571. doi: 10.1177/03331024211053571.
    >> Share

  192. PARAKRAMAWEERA R, Evans RW, Schor LI, Pearson SM, et al
    A brief diagnostic screen for cluster headache: Creation and initial validation of the Erwin Test for Cluster Headache.
    Cephalalgia. 2021;41:1298-1309.
    >> Share

    October 2021
  193. HAPPOLA P, Gormley P, Nuottamo ME, Artto V, et al
    Polygenic risk provides biological validity for the ICHD-3 criteria among Finnish migraine families.
    Cephalalgia. 2021 Oct 14:3331024211045651. doi: 10.1177/03331024211045651.
    >> Share

  194. OVEREEM LH, Peikert A, Hofacker MD, Kamm K, et al
    Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.
    Cephalalgia. 2021 Oct 13:3331024211048765. doi: 10.1177/03331024211048765.
    >> Share

  195. MESSINA R, Rocca MA, Valsasina P, Misci P, et al
    Clinical correlates of hypothalamic functional changes in migraine patients.
    Cephalalgia. 2021 Oct 13:3331024211046618. doi: 10.1177/03331024211046618.
    >> Share

  196. KANG L, Tang W, Zhang Y, Zhang M, et al
    The gut microbiome modulates nitroglycerin-induced migraine-related hyperalgesia in mice.
    Cephalalgia. 2021 Oct 13:3331024211050036. doi: 10.1177/03331024211050036.
    >> Share

  197. REUTER U, Krege JH, Lombard L, Gomez Valderas E, et al
    Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study.
    Cephalalgia. 2021 Oct 13:3331024211048507. doi: 10.1177/03331024211048507.
    >> Share

  198. ALPUENTE A, Gallardo VJ, Asskour L, Caronna E, et al
    Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks.
    Cephalalgia. 2021 Oct 4:3331024211040467. doi: 10.1177/03331024211040467.
    >> Share

  199. FRANK F, Ulmer H, Sidoroff V, Broessner G, et al
    CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis.
    Cephalalgia. 2021;41.
    >> Share

  200. TANHA HM, Martin NG, Whitfield JB, Nyholt DR, et al
    Association and genetic overlap between clinical chemistry tests and migraine.
    Cephalalgia. 2021;41.
    >> Share

  201. GONZALEZ-QUINTANILLA V, Perez-Pereda S, Gonzalez-Suarez A, Madera J, et al
    Restless legs-like syndrome as an emergent adverse event of CGRP monoclonal antibodies: A report of two cases.
    Cephalalgia. 2021;41.
    >> Share

  202. VAN CASTEREN DS, Verhagen IE, de Boer I, de Vries Lentsch S, et al
    E-diary use in clinical headache practice: A prospective observational study.
    Cephalalgia. 2021;41.
    >> Share

    September 2021
  203. LOBO R, Wang M, Lobo S, Bahra A, et al
    Time to retire 'New daily persistent headache': Mode of onset of chronic migraine and tension-type headache.
    Cephalalgia. 2021 Sep 27:3331024211044440. doi: 10.1177/03331024211044440.
    >> Share

  204. KIM S, Lee SB, Hong YJ, Kim Y, et al
    The influence of endogenous and exogenous hormonal factors on migraine in spontaneous postmenopausal women: A nationwide population-based study in South Korea.
    Cephalalgia. 2021 Sep 27:3331024211044441. doi: 10.1177/03331024211044441.
    >> Share

  205. CHOWDHURY D, Bansal L, Duggal A, Datta D, et al
    TOP-PRO study: A randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine.
    Cephalalgia. 2021 Sep 27:3331024211047454. doi: 10.1177/03331024211047454.
    >> Share

  206. RAFFAELLI B, Terhart M, Overeem LH, Mecklenburg J, et al
    Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study.
    Cephalalgia. 2021 Sep 27:3331024211046617. doi: 10.1177/03331024211046617.
    >> Share

  207. INAN LE, Inan N
    Greater occipital nerve block in migraine may have a place in migraine treatment.
    Cephalalgia. 2021 Sep 23:3331024211045644. doi: 10.1177/03331024211045644.
    >> Share

  208. BOTTIROLI S, Galli F, Ballante E, Pazzi S, et al
    Validity of the Severity of Dependence Scale for detecting dependence behaviours in chronic migraine with medication overuse.
    Cephalalgia. 2021 Sep 20:3331024211039817. doi: 10.1177/03331024211039817.
    >> Share

  209. PUTANANICKAL N, Gross EC, Orsini AL, Schmidt S, et al
    Efficacy and safety of exogenous beta-hydroxybutyrate for preventive treatment in episodic migraine: A single-centred, randomised, placebo-controlled, double-blind crossover trial.
    Cephalalgia. 2021 Sep 20:3331024211043792. doi: 10.1177/03331024211043792.
    >> Share


  210. CORRIGENDUM to 'Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis'.
    Cephalalgia. 2021 Sep 14:3331024211042798. doi: 10.1177/03331024211042798.
    >> Share

  211. SCHWEDT TJ, Lipton RB, Ailani J, Silberstein SD, et al
    Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.
    Cephalalgia. 2021 Sep 14:3331024211042385. doi: 10.1177/03331024211042385.
    >> Share

  212. IKEGAMI D, Navratilova E, Yue X, Moutal A, et al
    A prolactin-dependent sexually dimorphic mechanism of migraine chronification.
    Cephalalgia. 2021 Sep 12:3331024211039813. doi: 10.1177/03331024211039813.
    >> Share

    August 2021
  213. LIPTON RB, Dodick DW, Kudrow D, Reuter U, et al
    Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies.
    Cephalalgia. 2021 Aug 18:3331024211028966. doi: 10.1177/03331024211028966.
    >> Share

  214. TFELT-HANSEN P, Jorgensen K, Diener HC
    Doubtful use of placebo following placebo in recent controlled trials of lasmiditan and ubrogepant for the treatment of migraine attacks.
    Cephalalgia. 2021 Aug 18:3331024211029939. doi: 10.1177/03331024211029939.
    >> Share

  215. CHRISTENSEN SL, Rasmussen RH, Ernstsen C, La Cour S, et al
    CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine.
    Cephalalgia. 2021 Aug 18:3331024211038884. doi: 10.1177/03331024211038884.
    >> Share

  216. PENG KP, Schellong M, May A
    Aura in trigeminal autonomic cephalalgia is probably mediated by comorbid migraine with aura.
    Cephalalgia. 2021 Aug 18:3331024211030499. doi: 10.1177/03331024211030499.
    >> Share

  217. GIL-GOUVEIA R, Oliveira AG
    Are PROMs passing the message? A reflection with real-life migraine patients.
    Cephalalgia. 2021 Aug 18:3331024211034509. doi: 10.1177/03331024211034509.
    >> Share

  218. ROZEN TD, Bhatt AA
    Reversible cerebral vasoconstriction syndrome developing after an erenumab injection for migraine prevention.
    Cephalalgia. 2021 Aug 18:3331024211037277. doi: 10.1177/03331024211037277.
    >> Share

  219. BEIER D, Callesen HE, Carlsen LN, Birkefoss K, et al
    Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education in migraine treatment. A systematic review and meta-analysis.
    Cephalalgia. 2021 Aug 18:3331024211034489. doi: 10.1177/03331024211034489.
    >> Share

  220. MARTINELLI D, Arceri S, De Icco R, Allena M, et al
    BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm.
    Cephalalgia. 2021 Aug 18:3331024211034508. doi: 10.1177/03331024211034508.
    >> Share

  221. MCGINLEY JS, Savord A, Houts CR, Wirth RJ, et al
    What do people want to know about "Growing Up with Migraine"? Results of a preference survey of people with lived experience to guide future research.
    Cephalalgia. 2021 Aug 18:3331024211038526. doi: 10.1177/03331024211038526.
    >> Share

  222. AL-HASSANY L, Vries T, Carpay JA, MaassenVanDenBrink A, et al
    Could erectile dysfunction be a side effect of CGRP inhibition? A case report.
    Cephalalgia. 2021 Aug 18:3331024211037304. doi: 10.1177/03331024211037304.
    >> Share

  223. REIDY BL, Peugh J, Hershey AD, Coffey CS, et al
    Trajectory of treatment response in the child and adolescent migraine prevention (CHAMP) study: A randomized clinical trial.
    Cephalalgia. 2021 Aug 17:3331024211033551. doi: 10.1177/03331024211033551.
    >> Share

  224. MILOSEVIC N, Trajkovic JZ, Mijajlovic M, Milosevic J, et al
    The first prevalence study of primary headaches in adults in a post-conflict area of Serbia.
    Cephalalgia. 2021;41:959-967.
    >> Share

  225. HUTCHINSON S, Silberstein SD, Blumenfeld AM, Lipton RB, et al
    Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II.
    Cephalalgia. 2021;41:979-990.
    >> Share

  226. MEHTA DG, Garza I, Robertson CE
    Two hundred and forty-eight cases of visual snow: A review of potential inciting events and contributing comorbidities.
    Cephalalgia. 2021;41:1015-1026.
    >> Share

    July 2021
  227. TFELT-HANSEN P
    Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review.
    Cephalalgia. 2021 Jul 18:3331024211028959. doi: 10.1177/03331024211028959.
    >> Share

  228. ROXAS A JR, Quiles LE, Wang SJ
    Delivery of care for migraine in the Asian Oceanian region: A cross-sectional study.
    Cephalalgia. 2021 Jul 18:3331024211024153. doi: 10.1177/03331024211024153.
    >> Share

  229. CERAMI C, Crespi C, Bottiroli S, Santi GC, et al
    High perceived isolation and reduced social support affect headache impact levels in migraine after the Covid-19 outbreak: A cross sectional survey on chronic and episodic patients.
    Cephalalgia. 2021 Jul 13:3331024211027568. doi: 10.1177/03331024211027568.
    >> Share

  230. AKERMAN S, Salvemini D, Romero-Reyes M
    Targeting reactive nitroxidative species in preclinical models of migraine.
    Cephalalgia. 2021 Jul 13:3331024211017884. doi: 10.1177/03331024211017884.
    >> Share

  231. DAVIDSSON OB, Olofsson IA, Kogelman LJ, Andersen MA, et al
    Twenty-five years of triptans - a nationwide population study.
    Cephalalgia. 2021;41:894-904.
    >> Share

    June 2021
  232. MACKENZIE KD, Stratton JR
    Response to letter to the Editor: Assessing migraine therapeutics.
    Cephalalgia. 2021 Jun 30:3331024211021563. doi: 10.1177/03331024211021563.
    >> Share

  233. XU C, Bussiere J
    Assessing migraine therapeutics.
    Cephalalgia. 2021 Jun 30:3331024211021569. doi: 10.1177/03331024211021569.
    >> Share

  234. WANG SJ, Roxas AA Jr, Saravia B, Kim BK, et al
    Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study.
    Cephalalgia. 2021 Jun 25:3331024211024160. doi: 10.1177/03331024211024160.
    >> Share

  235. GERSTL L, Tadych N, Heinen F, Kainz C, et al
    Migraine and the development of additional psychiatric and pain disorders in the transition from adolescence to adulthood.
    Cephalalgia. 2021 Jun 23:3331024211021792. doi: 10.1177/03331024211021792.
    >> Share

  236. BENBOW T, Cairns BE
    Dysregulation of the peripheral glutamatergic system: A key player in migraine pathogenesis?
    Cephalalgia. 2021 Jun 20:3331024211017882. doi: 10.1177/03331024211017882.
    >> Share

  237. FRESE A, Summ O, Evers S
    CGRP release in an experimental human trigeminal pain model.
    Cephalalgia. 2021 Jun 20:3331024211017250. doi: 10.1177/03331024211017250.
    >> Share

  238. LENGYEL M, Hajdu D, Dobolyi A, Rosta J, et al
    TRESK background potassium channel modifies the TRPV1-mediated nociceptor excitability in sensory neurons.
    Cephalalgia. 2021;41:827-838.
    >> Share

  239. CONSTANTINIDIS TS, Arvaniti C, Fakas N, Rudolf J, et al
    A population-based survey for disabling headaches in Greece: Prevalence, burden and treatment preferences.
    Cephalalgia. 2021;41:810-820.
    >> Share

    May 2021
  240. COHEN-BARAK O, Radivojevic A, Jones A, Fiedler-Kelly J, et al
    Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach.
    Cephalalgia. 2021 May 17:3331024211007789. doi: 10.1177/03331024211007789.
    >> Share

  241. GANTENBEIN AR, Agosti R, Gobbi C, Flugel D, et al
    Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study.
    Cephalalgia. 2021 May 17:3331024211014616. doi: 10.1177/03331024211014616.
    >> Share

  242. TASSORELLI C, Diener HC, Silberstein SD, Dodick DW, et al
    Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine.
    Cephalalgia. 2021 May 14:3331024211010413. doi: 10.1177/03331024211010413.
    >> Share

  243. WILKINS AJ, Haigh SM, Mahroo OA, Plant GT, et al
    Photophobia in migraine: A symptom cluster?
    Cephalalgia. 2021 May 14:3331024211014633. doi: 10.1177/03331024211014633.
    >> Share

  244. PAZDERA L, Cohen JM, Ning X, Campos VR, et al
    Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response.
    Cephalalgia. 2021 May 14:3331024211008401. doi: 10.1177/03331024211008401.
    >> Share

  245. LIPTON RB, Burstein R, Buse DC, Dodick DW, et al
    Efficacy of erenumab in chronic migraine patients with and without ictal allodynia.
    Cephalalgia. 2021 May 13:3331024211010305. doi: 10.1177/03331024211010305.
    >> Share


  246. CORRIGENDUM to 'Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN'.
    Cephalalgia. 2021 May 5:3331024211015848. doi: 10.1177/03331024211015848.
    >> Share

  247. DIENER HC, Ashina M, Ritter S, Paiva Da Silva Lima G, et al
    Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study.
    Cephalalgia. 2021 May 3:3331024211010308. doi: 10.1177/03331024211010308.
    >> Share

  248. YOUNG AS, Nham B, Bradshaw AP, Calic Z, et al
    Clinical, oculographic, and vestibular test characteristics of vestibular migraine.
    Cephalalgia. 2021 May 2:3331024211006042. doi: 10.1177/03331024211006042.
    >> Share

  249. SCHWEDT TJ, Sahai-Srivastava S, Murinova N, Birlea M, et al
    Determinants of pain interference and headache impact in patients who have chronic migraine with medication overuse: Results from the MOTS trial.
    Cephalalgia. 2021 May 2:3331024211006903. doi: 10.1177/03331024211006903.
    >> Share

    April 2021
  250. CHONG CD, Berisha V, Ross K, Kahn M, et al
    Distinguishing persistent post-traumatic headache from migraine: Classification based on clinical symptoms and brain structural MRI data.
    Cephalalgia. 2021 Apr 29:333102421991819. doi: 10.1177/0333102421991819.
    >> Share

  251. POHL H, Benemei S, Garcia-Azorin D, Dixon J, et al
    Time lost due to an attack - a novel patient-reported outcome measure for acute migraine treatments.
    Cephalalgia. 2021 Apr 19:3331024211006048. doi: 10.1177/03331024211006048.
    >> Share

  252. RAOOF N, Hoffmann J
    Diagnosis and treatment of idiopathic intracranial hypertension.
    Cephalalgia. 2021;41:472-478.
    >> Share

  253. CERIANI CE, Silberstein SD
    Headache and rhinosinusitis: A review.
    Cephalalgia. 2021;41:453-463.
    >> Share

    March 2021
  254. ROTHROCK JF, Diener HC
    Headache secondary to cerebrovascular disease.
    Cephalalgia. 2021 Mar 18:333102421999045. doi: 10.1177/0333102421999045.
    >> Share

  255. ZHANG Y, Zhao X, Wang Y, Dong Z, et al
    Prevalence and characteristics of cough headache in a Chinese respiratory clinic.
    Cephalalgia. 2021;41:366-374.
    >> Share

  256. VINOGRADOVA LV, Suleymanova EM, Medvedeva TM
    Transient loss of interhemispheric functional connectivity following unilateral cortical spreading depression in awake rats.
    Cephalalgia. 2021;41:353-365.
    >> Share

    February 2021
  257. SHAH R, Assis F, Narasimhan B, Khachadourian V, et al
    Trans-nasal high-flow dehumidified air in acute migraine headaches: A randomized controlled trial.
    Cephalalgia. 2021 Feb 25:333102421997766. doi: 10.1177/0333102421997766.
    >> Share

  258. WANG X, Yin Z, Lian Y, Xu Y, et al
    Premonitory symptoms in migraine from China: A multi-clinic study of 4821 patients.
    Cephalalgia. 2021 Feb 25:333102421997850. doi: 10.1177/0333102421997850.
    >> Share

  259. BHAKTA M, Vuong T, Taura T, Wilson DS, et al
    Migraine therapeutics differentially modulate the CGRP pathway.
    Cephalalgia. 2021 Feb 24:333102420983282. doi: 10.1177/0333102420983282.
    >> Share

  260. SOLLMANN N, Schandelmaier P, Weidlich D, Borner C, et al
    Patients with episodic migraine show increased T2 values of the trapezius muscles - an investigation by quantitative high-resolution magnetic resonance imaging.
    Cephalalgia. 2021 Feb 20:333102421996374. doi: 10.1177/0333102421996374.
    >> Share

  261. SOUTHWELL J, Afridi SK
    The burden of migraine on acute and emergency services in a London teaching hospital.
    Cephalalgia. 2021 Feb 18:333102420981734. doi: 10.1177/0333102420981734.
    >> Share

  262. DE TOMMASO M, Delussi M, Gentile E, Ricci K, et al
    Effect of single dose Erenumab on cortical responses evoked by cutaneous a-delta fibers: A pilot study in migraine patients.
    Cephalalgia. 2021 Feb 16:333102421996345. doi: 10.1177/0333102421996345.
    >> Share

  263. DRELLIA K, Kokoti L, Deligianni CI, Papadopoulos D, et al
    Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis.
    Cephalalgia. 2021 Feb 10:333102421989601. doi: 10.1177/0333102421989601.
    >> Share

  264. WIENHOLTZ NKF, Christensen CE, Zhang DG, Coskun H, et al
    Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial.
    Cephalalgia. 2021 Feb 10:333102420975395. doi: 10.1177/0333102420975395.
    >> Share

  265. TCHIVILEVA IE, Ohrbach R, Fillingim RB, Lim PF, et al
    Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial.
    Cephalalgia. 2021 Feb 9:333102421989268. doi: 10.1177/0333102421989268.
    >> Share

  266. ASHINA M, Reuter U, Smith T, Krikke-Workel J, et al
    Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study.
    Cephalalgia. 2021 Feb 4:333102421989232. doi: 10.1177/0333102421989232.
    >> Share

  267. LISICKI M, Figuerola ML, Bonamico L, Lew D, et al
    The prevalence of migraine in Argentina: A reappraisal.
    Cephalalgia. 2021 Feb 1:333102421989262. doi: 10.1177/0333102421989262.
    >> Share

  268. CHO S, Cho SJ, Lee MJ, Park JW, et al
    Clinical characteristics of pre-attack symptoms in cluster headache: A large series of Korean patients.
    Cephalalgia. 2021;41:227-236.
    >> Share

    January 2021
  269. DIENER HC, Ashina M, Durand-Zaleski I, Kurth T, et al
    Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society.
    Cephalalgia. 2021 Jan 20:333102421989247. doi: 10.1177/0333102421989247.
    >> Share

  270. CATARCI T
    Occipital ischaemic stroke after visual snow phenomenon - a case report.
    Cephalalgia. 2021 Jan 12:333102420985444. doi: 10.1177/0333102420985444.
    >> Share

  271. VERHAGEN IE, van Casteren DS, Lentsch SV, Terwindt GM, et al
    Effect of lockdown during COVID-19 on migraine: A longitudinal cohort study.
    Cephalalgia. 2021 Jan 11:333102420981739. doi: 10.1177/0333102420981739.
    >> Share

  272. KARSAN N, Perez-Rodriguez A, Nagaraj K, Bose PR, et al
    The migraine postdrome: Spontaneous and triggered phenotypes.
    Cephalalgia. 2021 Jan 10:333102420975401. doi: 10.1177/0333102420975401.
    >> Share

  273. MELO-CARRILLO A, Strassman AM, Schain AJ, Adams AM, et al
    Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons.
    Cephalalgia. 2021;41:17-32.
    >> Share

  274. LEHMAN LL, Bruccoleri R, Danehy A, Swanson J, et al
    Adverse effects of erenumab on cerebral proliferative angiopathy: A case report.
    Cephalalgia. 2021;41:122-126.
    >> Share

    December 2020
  275. ILJAZI A, Ashina H, Zhuang ZA, Lopez Lopez C, et al
    Hypersensitivity to calcitonin gene-related peptide in chronic migraine.
    Cephalalgia. 2020 Dec 15:333102420981666. doi: 10.1177/0333102420981666.
    >> Share

  276. BEGASSE DE DHAEM O, Gharedaghi MH, Bain P, Hettie G, et al
    Identification of work accommodations and interventions associated with work productivity in adults with migraine: A scoping review.
    Cephalalgia. 2020 Dec 10:333102420977852. doi: 10.1177/0333102420977852.
    >> Share

  277. STRANG-KARLSSON S, Alenius S, Nasanen-Gilmore P, Nurhonen M, et al
    Migraine in children and adults born preterm: A nationwide register linkage study.
    Cephalalgia. 2020 Dec 9:333102420978357. doi: 10.1177/0333102420978357.
    >> Share

  278. POZO-ROSICH P, Coppola G, Pascual J, Schwedt TJ, et al
    How does the brain change in chronic migraine? Developing disease biomarkers.
    Cephalalgia. 2020 Dec 8:333102420974359. doi: 10.1177/0333102420974359.
    >> Share

  279. SCHRAMM S, Tenhagen I, Schmidt B, Holle-Lee D, et al
    Prevalence and risk factors of migraine and non-migraine headache in older people - results of the Heinz Nixdorf Recall study.
    Cephalalgia. 2020 Dec 3:333102420977183. doi: 10.1177/0333102420977183.
    >> Share

  280. IRIMIA P, Martinez-Valbuena I, Minguez-Olaondo A, Dominguez-Vivero C, et al
    Interictal amylin levels in chronic migraine patients: A case-control study.
    Cephalalgia. 2020 Dec 3:333102420977106. doi: 10.1177/0333102420977106.
    >> Share

  281. LIPTON RB, Tepper SJ, Silberstein SD, Kudrow D, et al
    Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension.
    Cephalalgia. 2020 Dec 3:333102420973994. doi: 10.1177/0333102420973994.
    >> Share

  282. WOOD ME, Burch RC, Hernandez-Diaz S
    Polypharmacy and comorbidities during pregnancy in a cohort of women with migraine.
    Cephalalgia. 2020 Dec 3:333102420975394. doi: 10.1177/0333102420975394.
    >> Share

  283. GROENKE BR, Daline IH, Nixdorf DR
    SUNCT/SUNA: Case series presenting in an orofacial pain clinic.
    Cephalalgia. 2020 Dec 3:333102420977292. doi: 10.1177/0333102420977292.
    >> Share

    November 2020
  284. GOADSBY PJ, Blumenfeld AM, Lipton RB, Dodick DW, et al
    Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications.
    Cephalalgia. 2020 Nov 26:333102420970523. doi: 10.1177/0333102420970523.
    >> Share

  285. GHANIZADA H, Iljazi A, Ashina H, Do TP, et al
    Nocebo response in human models of migraine: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled, two-way crossover trials in migraine without aura and healthy volunteers.
    Cephalalgia. 2020 Nov 26:333102420970489. doi: 10.1177/0333102420970489.
    >> Share

  286. ASHINA M, Dolezil D, Bonner JH, Zhou L, et al
    A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention.
    Cephalalgia. 2020 Nov 24:333102420970889. doi: 10.1177/0333102420970889.
    >> Share

  287. VAN CASTEREN DS, Verhagen IE, Onderwater GL, MaassenVanDenBrink A, et al
    Sex differences in prevalence of migraine trigger factors: A cross-sectional study.
    Cephalalgia. 2020 Nov 17:333102420974362. doi: 10.1177/0333102420974362.
    >> Share

  288. WANG SJ, Wu JW
    Reversion from chronic migraine to episodic migraine: A new outcome measure.
    Cephalalgia. 2020 Nov 17:333102420974004. doi: 10.1177/0333102420974004.
    >> Share

  289. GOLLION C, Gazagnes J, Fabry V, Barbieux-Guillot M, et al
    Atrial fibrillation and migraine with aura in young adults with ischemic stroke.
    Cephalalgia. 2020 Nov 17:333102420970880. doi: 10.1177/0333102420970880.
    >> Share

  290. CARVALHO GF, Luedtke K, Szikszay TM, Bevilaqua-Grossi D, et al
    Muscle endurance training of the neck triggers migraine attacks.
    Cephalalgia. 2020 Nov 17:333102420970184. doi: 10.1177/0333102420970184.
    >> Share

  291. LACKOVIC J, Price TJ, Dussor G
    De novo protein synthesis is necessary for priming in preclinical models of migraine.
    Cephalalgia. 2020 Nov 17:333102420970514. doi: 10.1177/0333102420970514.
    >> Share

  292. MASTRIA G, Mancini V, Cesare MD, Puma M, et al
    Prevalence and characteristics of Alice in Wonderland Syndrome in adult migraineurs: Perspectives from a tertiary referral headache unit.
    Cephalalgia. 2020 Nov 9:333102420968245. doi: 10.1177/0333102420968245.
    >> Share

  293. DODICK DW, Doty EG, Aurora SK, Ruff DD, et al
    Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine.
    Cephalalgia. 2020 Nov 3:333102420966658. doi: 10.1177/0333102420966658.
    >> Share

  294. KOPRUSZINSKI CM, Thornton P, Arnold J, Newton P, et al
    Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine.
    Cephalalgia. 2020 Nov 1:333102420966581. doi: 10.1177/0333102420966581.
    >> Share

  295. PETRUSIC I, Zidverc-Trajkovic J
    Redefining types of migraine aura.
    Cephalalgia. 2020 Nov 1:333102420970186. doi: 10.1177/0333102420970186.
    >> Share

  296. LEVINE A, Vanderah TW, Largent-Milnes TM
    An underrepresented majority: A systematic review utilizing allodynic criteria to examine the present scarcity of discrete animal models for episodic migraine.
    Cephalalgia. 2020 Nov 1:333102420966984. doi: 10.1177/0333102420966984.
    >> Share

    October 2020
  297. LINSTRA KM, Ibrahimi K, van Casteren DS, Wermer MJ, et al
    Pain perception in women with menstrually-related migraine.
    Cephalalgia. 2020 Oct 21:333102420966977. doi: 10.1177/0333102420966977.
    >> Share

  298. ERNSTSEN C, Christensen SL, Olesen J, Kristensen DM, et al
    No additive effect of combining sumatriptan and olcegepant in the GTN mouse model of migraine.
    Cephalalgia. 2020 Oct 15:333102420963857. doi: 10.1177/0333102420963857.
    >> Share

  299. RIST PM, Bernstein C, Kowalski M, Osypiuk K, et al
    Multimodal chiropractic care for migraine: A pilot randomized controlled trial.
    Cephalalgia. 2020 Oct 13:333102420963844. doi: 10.1177/0333102420963844.
    >> Share

  300. ZELE AJ, Dey A, Adhikari P, Feigl B, et al
    Melanopsin hypersensitivity dominates interictal photophobia in migraine.
    Cephalalgia. 2020 Oct 12:333102420963850. doi: 10.1177/0333102420963850.
    >> Share


  301. Migraine Trust Virtual 2020 - Author index.
    Cephalalgia. 2020;40.
    >> Share

  302. PERES MF, Evers S
    Using social media and search engine data in headache research.
    Cephalalgia. 2020;40:1274-1275.
    >> Share

    September 2020
  303. ZAGAMI AS, Shaikh S, Mahns D, Lambert GA, et al
    A potential role for two brainstem nuclei in craniovascular nociception and the triggering of migraine headache.
    Cephalalgia. 2020 Sep 29:333102420960039. doi: 10.1177/0333102420960039.
    >> Share

  304. KOPRUSZINSKI CM, Navratilova E, Swiokla J, Dodick DW, et al
    A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain.
    Cephalalgia. 2020 Sep 26:333102420959794. doi: 10.1177/0333102420959794.
    >> Share

  305. SMITH JH
    Have you ever experienced a headache of any kind?
    Cephalalgia. 2020;40:1132-1133.
    >> Share

    July 2020
  306. LIU Y, Wang M, Bian X, Qiu E, et al
    Proposed modified diagnostic criteria for recurrent painful ophthalmoplegic neuropathy: Five case reports and literature review.
    Cephalalgia. 2020 Jul 28:333102420944872. doi: 10.1177/0333102420944872.
    >> Share

    December 2019
  307. HVEDSTRUP J, Kolding LT, Younis S, Ashina M, et al
    Ictal neck pain investigated in the interictal state - a search for the origin of pain.
    Cephalalgia. 2019 Dec 18:333102419896369. doi: 10.1177/0333102419896369.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016